Replies to post #205616 on Biotech Values

[DewDiligence]

Why is Viekira doing better ex-US vs Harvoni?

Almost all ex-US countries have a higher proportion of GT1b patients—where Viekira works best—than GT1a patients. The reverse is true in the US.